Study S000759

A Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy and Safety of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06937749
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 165
Start: 2025-07-01
Primary completion: 2026-04-30
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: DRUG:Placebo; DRUG:IBI362
Results posted: FALSE

Registered primary outcomes

Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology [Baseline, Week 60]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.